Verition Fund Management LLC

Position in PTGX — Protagonist Therapeutics, Inc

CIK 1454027 GREENWICH, CT

Back to PTGX Full portfolio

Position in PTGX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$1,243,328

-$1,096,685 QoQ

Shares Held

10,143

-62.1% QoQ

Ownership

0.016%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#170

of 341 holders

Holding Since

Jun 2023

6 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in PTGX Over Time

Shares Held

Position Value (USD)

Derivatives in PTGX

reported options exposure · as of Dec 31, 2025

CallValue

$3,144,240

CallShares

36,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Verition Fund Management LLC holds $152,220,097 across 64 Biotechnology names. PTGX ranks #25 (0.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	TECH	BIO-TECHNE Corp	438,746	$30,997,404
2	APGE	Apogee Therapeutics, Inc.	159,256	$21,138,048
3	ABVX	Abivax S.A.	105,791	$14,097,708
4	IDYA	IDEAYA Biosciences, Inc.	184,054	$6,859,692
5	SNDX	Syndax Pharmaceuticals Inc	304,939	$6,665,966
6	MRVI	Maravai Lifesciences Holdings, Inc.	777,738	$4,853,085
7	CYTK	Cytokinetics Inc	54,889	$4,675,993
8	RPRX	Royalty Pharma plc	75,000	$4,205,250

All Filings in PTGX

Export CSV

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,243,328	10,143	-62.1%	Shares	Sole	2026-08-14
2025-12-31	$3,144,240	36,000	—	Call	Sole	2026-02-13
2025-12-31	$2,340,013	26,792	+35.0%	Shares	Sole	2026-02-13
2025-03-31	$959,800	19,847	+82.2%	Shares	Sole	2025-05-15
2024-06-30	$377,511	10,895	+18.7%	Shares	Sole	2024-08-14
2024-03-31	$265,635	9,182	-0.3%	Shares	Sole	2024-05-14
2023-06-30	$254,380	9,210	—	Shares	Sole	2023-08-14
No filing history on record for this holder in this stock.